WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H462034
CAS#: 116308-56-6
Description: Watanipidine monohydrochloride is a is a calcium channel antagonist. It is used in the research of hypertensive disease.
Hodoodo Cat#: H462034
Name: Watanipidine monohydrochloride
CAS#: 116308-56-6
Chemical Formula: C41H43ClN4O6
Exact Mass: 722.29
Molecular Weight: 723.267
Elemental Analysis: C, 68.09; H, 5.99; Cl, 4.90; N, 7.75; O, 13.27
Synonym: Watanipidine monohydrochloride; Watanipidine HCl; AE0047
IUPAC/Chemical Name: 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(4-(4-(diphenylmethyl)-1-piperazinyl)phenyl)ethyl methyl ester, monohydrochloride
InChi Key: HEKGFDAQKCYYLS-UHFFFAOYSA-N
InChi Code: InChI=1S/C41H42N4O6.ClH/c1-28-36(40(46)50-3)38(33-15-10-16-35(27-33)45(48)49)37(29(2)42-28)41(47)51-26-21-30-17-19-34(20-18-30)43-22-24-44(25-23-43)39(31-11-6-4-7-12-31)32-13-8-5-9-14-32;/h4-20,27,38-39,42H,21-26H2,1-3H3;1H
SMILES Code: O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCC3=CC=C(N4CCN(C(C5=CC=CC=C5)C6=CC=CC=C6)CC4)C=C3.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 723.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Ashimori A, Ono T, Inoue Y, et al. Novel 1,4-dihydropyridine calcium antagonists. II. Synthesis and antihypertensive activity of 3-[4-(substituted amino)phenylalkyl]ester derivatives. Chem Pharm Bull (Tokyo). 1991;39(1):91‐99. doi:10.1248/cpb.39.91
2: Ashimori A, Uchida T, Ohtaki Y, et al. Synthesis and pharmacological effects of optically active 2-[4-(4-benzhydryl-1-piperazinyl)phenyl]-ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate hydrochloride. Chem Pharm Bull (Tokyo). 1991;39(1):108‐111. doi:10.1248/cpb.39.108.
3: Yamanaga K, Shinyama H, Akira T, et al. AE0047-mediated calcium channel blocking in vascular smooth muscles. Gen Pharmacol. 1997;29(3):337‐343. doi:10.1016/s0306-3623(96)00515-0.
4: Nishikawa M, Kubo Y, Kido H, Nakayama T, Nakamura N. Protection against endothelial abnormalities by a novel calcium channel blocker, AE0047, in stroke-prone spontaneously hypertensive rats. Gen Pharmacol. 1999;32(3):299‐305. doi:10.1016/s0306-3623(98)00180-3